Related Experiment Video
Updated: Jun 7, 2025

11:17
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
Published on: August 11, 2018
12.0K
Complete skin remission of Sneddon-Wilkinson disease with acalabrutinib
Harmeet K Bhullar1, Friyana Bhabha1, Chris McCormack1
1Sir Peter MacCallum Cancer Centre, Department of Dermatology, Melbourne, Victoria, Australia.
The Australasian Journal of Dermatology
|November 21, 2024
Abstract:
Sneddon-Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65-year-old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
